Ureteral Carcinoma in Situ After Successful Intravesical Therapy for Superficial Bladder Tumors: Incidence, Possible Pathogenesis and Management
Overview
Authors
Affiliations
A total of 66 patients with multifocal, progressive, flat carcinoma in situ of the bladder responded completely to intravesical bacillus Calmette-Guerin therapy for more than 1 year. Of the patients 19 (29 per cent) had clinical evidence of distal ureteral carcinoma in situ between 13 and 30 months (median 15 months) after bacillus Calmette-Guerin treatment. After evaluation of a positive urinary cytology study failed to reveal recurrent urothelial tumor of the bladder or prostatic urethral mucosa 6 patients underwent distal ureterectomy, 2 underwent nephroureterectomy, and 11 were managed by ureteroscopic resection and fulguration. In patients with carcinoma in situ of the bladder treated successfully with topical therapy the ureters represent a potential site of in situ carcinoma.
Soliman K, Taha D, Aboumarzouk O, Koraiem I, Shokeir A Arab J Urol. 2020; 18(3):155-162.
PMID: 33029425 PMC: 7473000. DOI: 10.1080/2090598X.2020.1751923.
Zhou H, Ro J, Truong L, Ayala A, Shen S Am J Clin Exp Urol. 2014; 2(2):156-60.
PMID: 25374918 PMC: 4219306.
Kim H, Moon K, Jeong C, Kwak C, Kim H, Ku J World J Urol. 2014; 33(3):359-65.
PMID: 24825471 DOI: 10.1007/s00345-014-1306-5.
Canda A, Dogan B, Atmaca A, Akbulut Z, Balbay M JSLS. 2012; 15(4):575-9.
PMID: 22643522 PMC: 3340976. DOI: 10.4293/108680811X13176785204751.
Gakis G, Schilling D, Perner S, Schwentner C, Sievert K, Stenzl A World J Urol. 2010; 29(4):451-6.
PMID: 20617438 DOI: 10.1007/s00345-010-0581-z.